Intravitreal sunitinib maleate- GrayBug Vision

Drug Profile

Intravitreal sunitinib maleate- GrayBug Vision

Alternative Names: GB 102- GrayBug Vision; GB 103- GrayBug Vision

Latest Information Update: 07 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GrayBug inc.
  • Class Amides; Antineoplastics; Ethylamines; Fluorobenzenes; Indoles; Pyrroles; Small molecules
  • Mechanism of Action Colony stimulating factor receptor antagonists; Fms-like tyrosine kinase 3 inhibitors; Platelet derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Age-related macular degeneration
  • Preclinical Diabetic macular oedema; Retinal vein occlusion

Most Recent Events

  • 06 Oct 2017 Chemical structure information added
  • 14 Sep 2017 Preclinical trials in Diabetic macular oedema in USA (Intravitreous)
  • 14 Sep 2017 Preclinical trials in Retinal vein occlusion in USA (Intravitreous)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top